News & Trade Shows

News & Trade shows

New Erythropoietin (EPO) ELISA Kit
New Erythropoietin (EPO) ELISA kit

IRVINE, Calif., October 7, 2010 -- BIOMERICA, INC. announced that it has launched an improved FDA-Cleared State of the art direct labeld Erythropoietin (EPO) ELISA kit with enhanced 0.6mIU/ml low end sensitivity. The assay is intended for in vitro diagnostic use, as an adjunct in determining cause of anemia and erythrocytosis (increase of red blood cell mass). Lower EPO levels than expected have been seen with anemias associated with the following conditions: rheumatoid arthritis, acquired immunodeficiency syndrome, cancer, ulcerative colitis, sickle cell disease, and in premature neonates.

Erythropoietin acts as the principal regulator in the production of red blood cells (erythrocytes) by controlling the number, the kinds, and the survival of the cells. Because of this ability, it is being investigated for use in cancer patients to prevent anemia, or to treat anemia that has been induced by chemotherapy and bone marrow transplantation.

The Biomerica EPO ELISA Kit contains microwell strips and enough reagents to test up to 88 patients for EPO.  The total assay time is only 2 hour and 30 minutes. The test is a state of the art direct label two-site ELISA and has a shelf life of 12 months when stored at 2-8°C.   

                #                   #                  #

Enclosed:  Data Sheet